A phase I/II open-label clinical trial of CPI-613 in combination with modified FOLFIRINOX in patients with locally advanced (LAPC) or borderline resectable pancreatic cancer (BRPC).
Publication/Presentation Date
5-2024
Volume
42
Issue
16
Published In/Presented At
Disciplines
Medicine and Health Sciences
Department(s)
Department of Surgery, Lehigh Valley Topper Cancer Institute
Document Type
Article
COinS